Nasdaq:US$17.93 (+1.56) | HKEX:HK$28.00 (+2.82) | AIM:£2.59 (+0.2)
搜索
搜索结果
上一篇文章   |   下一篇文章
公告及新闻稿, 肿瘤学 / 免疫学 | 2007-11-22

Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients